The 34th Academic Annual Meeting of the Chinese Chemical Society held from June 15th to 18th, 2024, in the vibrant city of Guangzhou, Guangdong Province.
Dr. Xiang Liu, CEO of Molefuture, captivated the audience with an in-depth presentation on the groundbreaking advancements in T7 RNA Polymerase research. She illuminated the huge potential of the Fluorescence-Activated Droplet Sorting (FADS) technology, highlighting its ultra-high-throughput and remarkable efficiency in reducing reagent usage, which is considered a game-changer for enzyme and strain modification. Dr. Liu also looked forward to the further evolution of T7 RNA Polymerase, such as to improve RNA integrity and reduce consumption of cap analogs.
The Annual Meeting served not only as an invaluable platform for industry professionals to exchange insights and foster collaboration but also as a cultural extravaganza that enriched the experience of all attendees. More importantly, it charted a course for the chemical research community to pursue ambitious new goals, propelling the industry towards an era of cutting-edge chemical innovation and discovery!
About US
Molefuture Biotechnology (Shanghai) Co., Ltd., a subsidiary of Yeasen Biotechnology (Shanghai) Co., Ltd., specializes in tailored enzyme modification solutions driven by cutting-edge enzyme evolution technologies. These solutions cater to diverse application needs in areas such as in vitro diagnostics, biopharmaceuticals, synthetic biology, medical aesthetics, pharmaceutical intermediates, and beyond.
For More Information
Tel： +86 133-0168-8701
Email：Support@molefuture.com